EGFR and non-small cell lung carcinoma: Amivantamab is used in combination with chemotherapy for patients with untreated non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion, or for those previously treated for NSCLC with a canonical EGFR mutation who experienced EGFR-tyrosine kinase inhibitor (TKI) failure (1, 2).